Patents by Inventor Rikke Baek Holmgaard

Rikke Baek Holmgaard has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CD200 RECEPTOR ANTAGONIST BINDING MOLECULES
    Publication number: 20220396619
    Abstract: The present invention relates to antagonist polypeptide molecules that bind to human CD200 receptor, and are useful for treating solid tumors, alone and in combination with chemotherapy, ionizing radiation, an antitumor agent and/or an immuno-oncology agent.
    Type: Application
    Filed: November 5, 2020
    Publication date: December 15, 2022
    Inventors: Katherine Marie BELL-MCGUINN, Stephen John DEMAREST, Kyla Elizabeth DRISCOLL, Rikke Baek HOLMGAARD, Anna Marie RUSSELL, Jaafar Nassar SLEIMAN HAIDAR, Derrick Ryan WITCHER
  • ANTI-PD-1 ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20220372149
    Abstract: The instant disclosure provides antibodies that specifically bind to human PD-1 and antagonize PD-1 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.
    Type: Application
    Filed: May 9, 2022
    Publication date: November 24, 2022
    Inventors: Marc VAN DIJK, Cornelia Anne MUNDT, Gerd RITTER, Jedd David WOLCHOK, Taha MERGHOUB, Roberta ZAPPASODI, Rikke Baek HOLMGAARD, David SCHAER, David Adam SAVITSKY, Nicholas Stuart WILSON
  • Anti-PD-1 antibodies and methods of use thereof
    Patent number: 11345755
    Abstract: The instant disclosure provides antibodies that specifically bind to human PD-1 and antagonize PD-1 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.
    Type: Grant
    Filed: April 24, 2020
    Date of Patent: May 31, 2022
    Assignees: Agenus Inc., Ludwig Institute for Cancer Research Ltd., Memorial Sloan-Kettering Cancer Center
    Inventors: Marc Van Dijk, Cornelia Anne Mundt, Gerd Ritter, Jedd David Wolchok, Taha Merghoub, Roberta Zappasodi, Rikke Bæk Holmgaard, David Schaer, David Adam Savitsky, Nicholas Stuart Wilson
  • ANTI-PD-1 ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20200354454
    Abstract: The instant disclosure provides antibodies that specifically bind to human PD-1 and antagonize PD-1 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.
    Type: Application
    Filed: April 24, 2020
    Publication date: November 12, 2020
    Inventors: Marc VAN DIJK, Cornelia Anne MUNDT, Gerd RITTER, Jedd David WOLCHOK, Taha MERGHOUB, Roberta ZAPPASODI, Rikke Bæk HOLMGAARD, David SCHAER, David Adam SAVITSKY, Nicholas Stuart WILSON
  • ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20200024350
    Abstract: Provided are antibodies that specifically bind to CTLA-4 and/or PD-1 and antagonize CTLA-4 and/or PD-1 function. Also provided are pharmaceutical compositions and kits comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies either alone or in combination.
    Type: Application
    Filed: June 7, 2019
    Publication date: January 23, 2020
    Inventors: Marc VAN DIJK, Cornelia Anne MUNDT, Gerd RITTER, David SCHAER, Jedd David WOLCHOK, Taha MERGHOUB, Nicholas Stuart WILSON, David Adam SAVITSKY, Mark Arthur FINDEIS, Roberta ZAPPASODI, Rikke Bæk HOLMGAARD, Jean-Marie CUILLEROT, Igor PROSCURSHIM, Olga SHEBANOVA
  • Anti-PD-1 antibodies and methods of use thereof
    Patent number: 10450373
    Abstract: The instant disclosure provides antibodies that specifically bind to human PD-1 and antagonize PD-1 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.
    Type: Grant
    Filed: April 30, 2019
    Date of Patent: October 22, 2019
    Assignees: AGENUS INC., LUDWIG INSTITUTE FOR CANCER RESEARCH LTD, MEMORIAL SLOAN KETTERING CANCER CENTER
    Inventors: Marc Van Dijk, Cornelia Anne Mundt, Gerd Ritter, Jedd David Wolchok, Taha Merghoub, Roberta Zappasodi, Rikke Baek Holmgaard, David Schaer, David Adam Savitsky, Nicholas Stuart Wilson
  • ANTI-PD-1 ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20190256601
    Abstract: The instant disclosure provides antibodies that specifically bind to human PD-1 and antagonize PD-1 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.
    Type: Application
    Filed: April 30, 2019
    Publication date: August 22, 2019
    Inventors: MARC VAN DIJK, CORNELIA ANNE MUNDT, GERD RITTER, JEDD DAVID WOLCHOK, TAHA MERGHOUB, ROBERTA ZAPPASODI, RIKKE BAEK HOLMGAARD, DAVID SCHAER, DAVID ADAM SAVITSKY, NICHOLAS STUART WILSON
  • Anti-PD-1 antibodies and methods of use thereof
    Patent number: 10323091
    Abstract: The instant disclosure provides antibodies that specifically bind to human PD-1 and antagonize PD-1 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.
    Type: Grant
    Filed: September 1, 2016
    Date of Patent: June 18, 2019
    Assignees: Agenus Inc., Memorial Sloan Kettering Cancer Center, Ludwig Institute for Cancer Research Ltd
    Inventors: Marc van Dijk, Nicholas Stuart Wilson, Cornelia Anne Mundt, Gerd Ritter, Jedd David Wolchok, Taha Merghoub, Roberta Zappasodi, Rikke Bæk Holmgaard, David Schaer, David Adam Savitsky
  • ANTI-PD-1 ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20170081409
    Abstract: The instant disclosure provides antibodies that specifically bind to human PD-1 and antagonize PD-1 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.
    Type: Application
    Filed: September 1, 2016
    Publication date: March 23, 2017
    Inventors: Marc van Dijk, Cornelia Anne Mundt, Gerd Ritter, Jedd David Wolchok, Taha Merghoub, Roberta Zappasodi, Rikke Bæk Holmgaard, David Schaer, David Adam Savitsky, Nicholas Stuart Wilson